In this article, we are going to take a look at where Evercore Inc. (NYSE:EVR) stands against other oversold financial stocks to buy right now. On March 7th, Federal Reserve Chairman Jerome Powell ...

On Friday, Evercore ISI reiterated its Outperform rating and $250.00 price target on Apple stock (current market cap: $3.43 trillion), highlighting the company's potential for an in-line quarter ...

CEO John Weinberg highlighted that 2024 was Evercore's second-best year for revenue, reaching over $3 billion in adjusted net revenues, with strength across all business segments. He noted the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

O n Monday, Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while maintaining an Outperform rating. The adjustment comes in ...

We’re dropping our coverage of Evercore. Morningstar provides research on approximately 1,500 publicly traded stocks, and we periodically revise our lists in response to client interest and ...

Investing.com -- Evercore ISI added Wendy’s Co to its Tactical Outperform list ahead of the company’s investor day on March 6, citing discounted valuation, a potential industry turnaround ...

Evercore ISI analyst Cory Kasimov reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) on February 28 and set a price target of $120.00. The company’s shares closed last Friday at $ ...

Evercore ISI analyst David Raso maintained a Sell rating on Illinois Tool Works (ITW – Research Report) yesterday and set a price target of $252.00. The company’s shares closed yesterday at $ ...

Evercore Inc.’s EVR fourth-quarter 2024 adjusted earnings per share of $3.41 surpassed the Zacks Consensus Estimate of $2.90. Also, the bottom line compared favorably with the prior-year quarter ...

(RTTNews) - Evercore Inc. (EVR) reported a profit for its fourth quarter that increased from last year and beat the Street estimates. The company's earnings came in at $140.44 million, or $3.30 ...

Evercore ISI has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to outperform from in line, citing upcoming catalysts. The investment firm said it was now including the CTX320 and CTX310 in vivo ...